Application of RNAi to Genomic Drug Target Validation in Schistosomes

Concerns over the possibility of resistance developing to praziquantel (PZQ), has stimulated efforts to develop new drugs for schistosomiasis. In addition to the development of improved whole organism screens, the success of RNA interference (RNAi) in schistosomes offers great promise for the identification of potential drug targets to initiate drug discovery. In this study we set out to contribute to RNAi based validation of putative drug targets. Initially a list of 24 target candidates was compiled based on the identification of putative essential genes in schistosomes orthologous of C. elegans essential genes. Knockdown of Calmodulin (Smp_026560.2) (Sm-Calm), that topped this list, produced a phenotype characterised by waves of contraction in adult worms but no phenotype in schistosomula. Knockdown of the atypical Protein Kinase C (Smp_096310) (Sm-aPKC) resulted in loss of viability in both schistosomula and adults and led us to focus our attention on other kinase genes that were identified in the above list and through whole organism screening of known kinase inhibitor sets followed by chemogenomic evaluation. RNAi knockdown of these kinase genes failed to affect adult worm viability but, like Sm-aPKC, knockdown of Polo-like kinase 1, Sm-PLK1 (Smp_009600) and p38-MAPK, Sm-MAPK p38 (Smp_133020) resulted in an increased mortality of schistosomula after 2-3 weeks, an effect more marked in the presence of human red blood cells (hRBC). For Sm-PLK-1 the same effects were seen with the specific inhibitor, BI2536, which also affected viable egg production in adult worms. For Sm-PLK-1 and Sm-aPKC the in vitro effects were reflected in lower recoveries in vivo. We conclude that the use of RNAi combined with culture with hRBC is a reliable method for evaluating genes important for larval development. However, in view of the slow manifestation of the effects of Sm-aPKC knockdown in adults and the lack of effects of Sm-PLK-1 and Sm-MAPK p38 on adult viability, these kinases may not represent suitable drug targets.

[1]  Liliana Rojo-Arreola,et al.  Chemical and Genetic Validation of the Statin Drug Target to Treat the Helminth Disease, Schistosomiasis , 2014, PloS one.

[2]  M. Berriman,et al.  Genetic and Molecular Basis of Drug Resistance and Species-Specific Drug Action in Schistosome Parasites , 2013, Science.

[3]  Ian H. Gilbert,et al.  Whole Organism High-Content Screening by Label-Free, Image-Based Bayesian Classification for Parasitic Diseases , 2012, PLoS neglected tropical diseases.

[4]  C. Dissous,et al.  SmSak, the Second Polo-Like Kinase of the Helminth Parasite Schistosoma mansoni: Conserved and Unexpected Roles in Meiosis , 2012, PloS one.

[5]  R. Greenberg,et al.  Genetic Knockdown and Pharmacological Inhibition of Parasite Multidrug Resistance Transporters Disrupts Egg Production in Schistosoma mansoni , 2011, PLoS neglected tropical diseases.

[6]  David S. Roos,et al.  TDR Targets: a chemogenomics resource for neglected diseases , 2011, Nucleic Acids Res..

[7]  D. Rollinson,et al.  A role for p38 mitogen-activated protein kinase in early post-embryonic development of Schistosoma mansoni. , 2011, Molecular and biochemical parasitology.

[8]  Bryan L. Roth,et al.  Chemical Informatics and Target Identification in a Zebrafish Phenotypic Screen , 2011, Nature chemical biology.

[9]  C. Caffrey,et al.  Schistosomiasis: from drug deployment to drug development , 2011, Current opinion in infectious diseases.

[10]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[11]  C. Dissous,et al.  Schistosoma mansoni Polo-like kinases and their function in control of mitosis and parasite reproduction. , 2011, Anais da Academia Brasileira de Ciencias.

[12]  T. Curiel,et al.  Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication. , 2011, Experimental parasitology.

[13]  J. Ruiz,et al.  Eukaryotic Protein Kinases (ePKs) of the Helminth Parasite Schistosoma mansoni , 2011, BMC Genomics.

[14]  Jin-ming Liu,et al.  RNAi silencing of calcium-regulated heat-stable protein of 24 kDa in Schistosoma japonicum affects parasite growth , 2011, Parasitology Research.

[15]  A. Taft,et al.  Cloning and Functional Characterization of Two Calmodulin Genes During Larval Development in the Parasitic Flatworm Schistosoma mansoni , 2011, The Journal of parasitology.

[16]  C. Dissous,et al.  Piggy-backing the concept of cancer drugs for schistosomiasis treatment: a tangible perspective? , 2011, Trends in parasitology.

[17]  David Rollinson,et al.  A role for p38 MAPK in the regulation of ciliary motion in a eukaryote , 2011, BMC Cell Biology.

[18]  Brian M. Suzuki,et al.  RNA Interference in Schistosoma mansoni Schistosomula: Selectivity, Sensitivity and Operation for Larger-Scale Screening , 2010, PLoS neglected tropical diseases.

[19]  David S. Roos,et al.  Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach , 2010, PLoS neglected tropical diseases.

[20]  Q. Bickle,et al.  Comparison of Microscopy and Alamar Blue Reduction in a Larval Based Assay for Schistosome Drug Screening , 2010, PLoS neglected tropical diseases.

[21]  S. Beckmann,et al.  Schistosoma mansoni Polo-like kinase 1: A mitotic kinase with key functions in parasite reproduction. , 2010, International journal for parasitology.

[22]  C. Shoemaker,et al.  Suppressing Glucose Transporter Gene Expression in Schistosomes Impairs Parasite Feeding and Decreases Survival in the Mammalian Host , 2010, PLoS pathogens.

[23]  M. Albonico,et al.  Praziquantel efficacy and long‐term appraisal of schistosomiasis control in Pemba Island , 2010, Tropical medicine & international health : TM & IH.

[24]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[25]  M. Gatton,et al.  Suppression of mRNAs Encoding Tegument Tetraspanins from Schistosoma mansoni Results in Impaired Tegument Turnover , 2010, PLoS pathogens.

[26]  A. Loukas,et al.  Transcriptional Changes in Schistosoma mansoni during Early Schistosomula Development and in the Presence of Erythrocytes , 2010, PLoS neglected tropical diseases.

[27]  Ning Ma,et al.  BLAST+: architecture and applications , 2009, BMC Bioinformatics.

[28]  J. Barrett,et al.  Anti-schistosomal Intervention Targets Identified by Lifecycle Transcriptomic Analyses , 2009, PLoS neglected tropical diseases.

[29]  J. Dalton,et al.  RNA interference targeting leucine aminopeptidase blocks hatching of Schistosoma mansoni eggs. , 2009, Molecular and biochemical parasitology.

[30]  P. Brindley,et al.  Culture for genetic manipulation of developmental stages of Schistosoma mansoni , 2009, Parasitology.

[31]  P. Skelly,et al.  RNA interference in schistosomes: machinery and methodology , 2009, Parasitology.

[32]  D. Rollinson,et al.  Protein kinase C signalling during miracidium to mother sporocyst development in the helminth parasite, Schistosoma mansoni. , 2009, International journal for parasitology.

[33]  G. Franco,et al.  Phenotypic Screen of Early-Developing Larvae of the Blood Fluke, Schistosoma mansoni, using RNA Interference , 2009, PLoS neglected tropical diseases.

[34]  B. Swierczewski,et al.  A Schistosome cAMP-Dependent Protein Kinase Catalytic Subunit Is Essential for Parasite Viability , 2009, PLoS neglected tropical diseases.

[35]  P. Skelly,et al.  The role of tegumental aquaporin from the human parasitic worm, Schistosoma monsoni, in osmoregulation and drug uptake , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  Sandra D. Melman,et al.  Reduced Susceptibility to Praziquantel among Naturally Occurring Kenyan Isolates of Schistosoma mansoni , 2009, PLoS neglected tropical diseases.

[37]  Y. Zhang,et al.  The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008 , 2009, Parasitology.

[38]  John P. Overington,et al.  The genome of the blood fluke Schistosoma mansoni , 2009, Nature.

[39]  D. Karanja,et al.  Impact of intense, longitudinal retreatment with praziquantel on cure rates of schistosomiasis mansoni in a cohort of occupationally exposed adults in western Kenya , 2009, Tropical medicine & international health : TM & IH.

[40]  David M. Glover,et al.  Polo-like kinases: conservation and divergence in their functions and regulation , 2009, Nature Reviews Molecular Cell Biology.

[41]  M. Doenhoff,et al.  Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs , 2009, Parasitology.

[42]  Richard J. Marhöfer,et al.  A Comparative Chemogenomics Strategy to Predict Potential Drug Targets in the Metazoan Pathogen, Schistosoma mansoni , 2009, PloS one.

[43]  Jürg Utzinger,et al.  Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis , 2008, Current opinion in infectious diseases.

[44]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[45]  Haiming Wang,et al.  SchistoDB: a Schistosoma mansoni genome resource , 2008, Nucleic Acids Res..

[46]  P. Brindley,et al.  Integration of reporter transgenes into Schistosoma mansoni chromosomes mediated by pseudotyped murine leukemia virus , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  A. Loukas,et al.  Can schistosomiasis really be consigned to history without a vaccine? , 2008, Vaccine.

[48]  Anton Simeonov,et al.  Identification of oxadiazoles as new drug leads for the control of schistosomiasis , 2008, Nature Medicine.

[49]  Alex Loukas,et al.  Current Status of Vaccines for Schistosomiasis , 2008, Clinical Microbiology Reviews.

[50]  G. Oliveira.  The Schistosoma mansoni transcriptome: an update. , 2007, Experimental parasitology.

[51]  P. Skelly,et al.  Protocols for gene silencing in schistosomes. , 2007, Experimental parasitology.

[52]  Solomon Nwaka,et al.  Schistosomes: challenges in compound screening , 2007, Expert opinion on drug discovery.

[53]  C. Shoemaker,et al.  Optimizing gene suppression in schistosomes using RNA interference. , 2007, Molecular and biochemical parasitology.

[54]  E. Davioud‐Charvet,et al.  Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target , 2007, PLoS medicine.

[55]  J. Vermunt,et al.  Assessing Performance of Orthology Detection Strategies Applied to Eukaryotic Genomes , 2007, PloS one.

[56]  R. Mortara,et al.  Protein tyrosine kinases in Schistosoma mansoni. , 2006, Memorias do Instituto Oswaldo Cruz.

[57]  R. Mortara,et al.  SmPKC1, a new protein kinase C identified in the platyhelminth parasite Schistosoma mansoni. , 2006, Biochemical and biophysical research communications.

[58]  G. Saunders,et al.  RNA interference in parasitic helminths: current situation, potential pitfalls and future prospects , 2006, Parasitology.

[59]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[60]  J. Muñoz,et al.  Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. , 2006, The American journal of tropical medicine and hygiene.

[61]  A. Coulson,et al.  Genomics in C. elegans: so many genes, such a little worm. , 2005, Genome research.

[62]  E. Pearce,et al.  Long-term suppression of cathepsin B levels by RNA interference retards schistosome growth. , 2005, Molecular and biochemical parasitology.

[63]  T. Day,et al.  Current status of sensitivity to praziquantel in a focus of potential drug resistance in Egypt. , 2005, International journal for parasitology.

[64]  M. Doenhoff,et al.  Determination of ED50 values for praziquantel in praziquantel-resistant and -susceptible Schistosoma mansoni isolates. , 2004, International journal for parasitology.

[65]  Hirohisa Hirai,et al.  Schistosoma mansoni genome project: an update. , 2004, Parasitology international.

[66]  F. Giostra,et al.  Methods and Results , 2014 .

[67]  M. Soares,et al.  Transcriptome analysis of the acoelomate human parasite Schistosoma mansoni , 2003, Nature Genetics.

[68]  C. Stoeckert,et al.  OrthoMCL: identification of ortholog groups for eukaryotic genomes. , 2003, Genome research.

[69]  C. Shoemaker,et al.  Using RNA interference to manipulate endogenous gene expression in Schistosoma mansoni sporocysts. , 2003, Molecular and biochemical parasitology.

[70]  A. Da'dara,et al.  Suppression of cathepsin B expression in Schistosoma mansoni by RNA interference. , 2003, International journal for parasitology.

[71]  Y. Dong,et al.  Systematic functional analysis of the Caenorhabditis elegans genome using RNAi , 2003, Nature.

[72]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[73]  K. Heidenreich,et al.  Pyridinylimidazole p38 mitogen-activated protein kinase inhibitors block intracellular Toxoplasma gondii replication. , 2002, International Journal of Parasitology.

[74]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[75]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[76]  J. Boissier,et al.  PCR effectiveness for sexing Schistosoma mansoni cercariae: application for sexing clonal cercarial populations. , 2001, Molecular and biochemical parasitology.

[77]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[78]  F. Abath.  Development of vaccines against human parasitic diseases: tools, current status and perspectives , 2000, Expert opinion on investigational drugs.

[79]  A. Deelder,et al.  Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. , 1997, The American journal of tropical medicine and hygiene.

[80]  A. Deelder,et al.  Efficacy and side effects of praziquantel in an epidemic focus of Schistosoma mansoni. , 1995, The American journal of tropical medicine and hygiene.

[81]  P. Basch.  Cultivation of Schistosoma mansoni in vitro. I. Establishment of cultures from cercariae and development until pairing. , 1981, The Journal of parasitology.

[82]  R. Humbert,et al.  Cultivation of Schistosoma mansoni in vitro. III. implantation of cultured worms into mouse mesenteric veins. , 1981, The Journal of parasitology.

[83]  G. Targett,et al.  Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. VIII Failure of concurrent infections with Plasmodium chabaudi to affect resistance to reinfection with S. mansoni. , 1981, Annals of tropical medicine and parasitology.

[84]  M. Doenhoff,et al.  Factors affecting the acquisition of resistance against Schistosoma mansoni in the mouse. I. Demonstration of resistance to reinfection using a model system that involves perfusion of mice within three weeks of challenge , 1978, Journal of Helminthology.

[85]  D J Rogers,et al.  A Computer Program for Classifying Plants. , 1960, Science.

[86]  A. Engel,et al.  PloS One 2012 , 2015 .

[87]  P. Skelly,et al.  Schistosoma mansoni: the dicer gene and its expression. , 2008, Experimental parasitology.

[88]  K. Yamaguchi,et al.  Hatching ofSchistosoma mansoni eggs is a Ca2+/calmodulin-dependent process , 2004, Parasitology Research.

[89]  K. Kojima,et al.  Possible roles of cAMP and Ca2+ in the regulation of miracidial transformation inSchistosoma mansoni , 2004, Parasitology Research.